Peptide 'glow up' claims on TikTok: what the science says
Quick answer
This video recommends five compounds for cosmetic and body composition goals, including Tesamorelin (FDA-approved for HIV lipodystrophy), an apparent reference to Retatrutide (still in Phase 2/3 trials with no approved indication), NAD+ (a coenzyme, not a peptide), an undefined 'glow stack,' and PT-141 (FDA-approved for hypoactive sexual desire disorder in premenopausal women). None of these compounds have regulatory approval for general summer wellness or cosmetic use, and at least one (Retatrutide) is not approved for any human use outside clinical trials. A board-certified provider and baseline labs are required before any of these should be considered.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @westendmedspa actually say?
The creator ran through a quick-hit list of five compounds they'd recommend for a "summer glow up." The list included Tesamorelin for "burning stubborn visceral fat," NAD+ for "a little bit of boost to energy and mental clarity," something called "reda" for fat loss described as "an absolute nuclear bomb," a vague "glow stack" covering skin, hair, nails, and anti-aging, and PT-141, introduced with the knowing wink "if you know you know." Five compounds, sixty seconds, zero dosing context, zero safety caveats. That's the whole pitch.
A few things jump out immediately. NAD+ is not a peptide. "Reda" is almost certainly Retatrutide, a GLP-1/GIP/glucagon triple agonist still in clinical trials. And PT-141, also known as bremelanotide, is an FDA-approved drug for hypoactive sexual desire disorder in women, not a cosmetic compound. Calling it a "glow up" tool is a creative reframe, to put it charitably.
Does the science back this up?
Some of it does, partially. Tesamorelin has the strongest evidence base here. It's FDA-approved specifically for HIV-associated lipodystrophy, and studies confirm it reduces visceral adipose tissue. The fat-loss claim isn't invented. But "stubborn visceral fat" in a general wellness context is a different population than the clinical trials studied.
NAD+ precursors like NMN and NR have shown some promise in early human trials, but calling NAD+ itself a peptide is flatly wrong. It's a coenzyme. Iyer et al. (2023, Aging Cell) found modest improvements in muscle function with NMN supplementation, but "energy and mental clarity" as a blanket benefit overstates the current evidence significantly.
Retatrutide, if that's what "reda" means, is not approved anywhere. Phase 2 data from Jastreboff et al. (2023, NEJM) showed up to 24% body weight reduction, which is genuinely remarkable, but it is an investigational drug. Calling it a bomb you'd casually recommend is irresponsible framing. The "glow stack" is never defined, which makes it impossible to evaluate. GHK-Cu has some legitimate skin-remodeling data (Pickart et al., 2015, Journal of Aging Science), but stacking unnamed compounds is not a verifiable claim.
What did they get wrong (or right)?
They got Tesamorelin's mechanism right. The visceral fat reduction data is real. Credit where it's due. But the framing of "stubborn visceral fat" for a general summer audience skips the part where this drug is studied in people with a specific medical condition, not healthy people who want to lean out before June.
Calling NAD+ a peptide is simply wrong. It's a basic categorization error that undermines the credibility of the whole list. NAD+ is a coenzyme involved in cellular energy metabolism, not a peptide chain.
"Reda" as a casual fat-loss recommendation is the most concerning item here. Retatrutide has no approved human use. Recommending investigational compounds to 621,000 viewers as a glow-up tool, with no clinical context, no mention of trial status, and no safety information, is exactly the kind of content that gets people into trouble with compounding pharmacies or gray-market suppliers.
PT-141 is FDA-approved, but not for skin or general wellness. It works on melanocortin receptors and is indicated for female sexual dysfunction. The "if you know you know" framing implies off-label use for libido, which is common in wellness circles, but presenting it as a cosmetic compound misleads viewers about what it actually does and how it's regulated.
What should you actually know?
Several of these compounds are either investigational, FDA-approved only for specific conditions, or not peptides at all. That matters because how a compound is regulated determines how it can legally be prescribed, compounded, and sold. Using an investigational drug like Retatrutide outside of a clinical trial means sourcing it from unregulated channels, which carries real risk.
Tesamorelin and PT-141 are legitimate pharmaceutical compounds, but they require a prescription and medical evaluation. NAD+ infusions and oral precursors are widely available, but the evidence for dramatic benefits in healthy adults is weaker than the wellness industry suggests. The "glow stack" is undefined, which should be a red flag in any clinical conversation.
If you're genuinely curious about any of these compounds, the conversation starts with a licensed provider who can review your labs, your health history, and whether the compound has a legitimate evidence base for your specific situation. A sixty-second TikTok list is not a treatment plan.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide 'glow up' claims on TikTok: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide 'glow up' claims on TikTok: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
This video recommends five compounds for cosmetic and body composition goals, including Tesamorelin (FDA-approved for HIV lipodystrophy), an apparent reference to Retatrutide (still in Phase 2/3 trials with no approved indication), NAD+ (a coenzyme, not a peptide), an undefined 'glow stack,' and PT-141 (FDA-approved for hypoactive sexual desire disorder in premenopausal women).
FormBlends verdict
This video recommends five compounds for cosmetic and body composition goals, including Tesamorelin (FDA-approved for HIV lipodystrophy), an apparent reference to Retatrutide (still in Phase 2/3 trials with no approved indication), NAD+ (a coenzyme, not a peptide), an undefined 'glow stack,' and PT-141 (FDA-approved for hypoactive sexual desire disorder in premenopausal women). None of these compounds have regulatory approval for general summer wellness or cosmetic use, and at least one (Retatrutide) is not approved for any human use outside clinical trials. A board-certified provider and baseline labs are required before any of these should be considered.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video recommends five compounds for cosmetic and body composition goals, including Tesamorelin (FDA-approved for HIV lipodystrophy), an apparent reference to Retatrutide (still in Phase 2/3 trials with no approved indication), NAD+ (a coenzyme, not a peptide), an undefined 'glow stack,' and PT-141 (FDA-approved for hypoactive sexual desire disorder in premenopausal women). None of these compounds have regulatory approval for general summer wellness or cosmetic use, and at least one (Retatrutide) is not approved for any human use outside clinical trials. A board-certified provider and baseline labs are required before any of these should be considered.
- Tesamorelin's visceral fat reduction is FDA-validated, but only in HIV-associated lipodystrophy patients. The evidence base for healthy adults pursuing cosmetic fat loss is not the same population studied in regulatory trials.
- NAD+ is a coenzyme, not a peptide. Listing it alongside peptides is a basic factual error. NMN and NR are the oral precursors most studied, and even those have modest human evidence.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Tesamorelin's visceral fat reduction is FDA-validated, but only in HIV-associated lipodystrophy patients. The evidence base for healthy adults pursuing cosmetic fat loss is not the same population studied in regulatory trials.
- NAD+ is a coenzyme, not a peptide. Listing it alongside peptides is a basic factual error. NMN and NR are the oral precursors most studied, and even those have modest human evidence.
- Retatrutide (likely 'reda') showed up to 24% weight loss in Jastreboff et al. (2023, NEJM Phase 2 data), but it has no approved indication anywhere. Sourcing it outside a clinical trial means buying from unregulated suppliers.
- PT-141 is a real FDA-approved drug (bremelanotide) for female sexual dysfunction, not a cosmetic peptide. Its melanocortin receptor mechanism is well-documented, but its approved use is narrow and prescription-only.
- GHK-Cu, often included in 'glow stacks,' has legitimate in-vitro and some clinical data for skin remodeling (Pickart et al., 2015), but compounded 'stacks' with unnamed ingredients cannot be evaluated for safety or effectiveness.
- All of the compounds in this video that have any approved use require a prescription and medical evaluation. A social media list is not a substitute for labs, a health history review, and a licensed provider conversation.
- The term 'glow up' is doing a lot of regulatory work in this video. Framing prescription and investigational compounds as cosmetic lifestyle tools does not change their legal classification or the risks involved in obtaining them without proper oversight.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
WestEnd MedSpa · TikTok creator
621.1K views on this video
Top 5 peps to glow up before summer ☀️✨ #skinhealth #summerglowup #longevity #glowup #skincare
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by WestEnd MedSpa, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.